09/23/2021
TMS MIGHT BE THE TREATMENT OF CHOICE FOR YOU IF
In January 2013 Brainsway received FDA approval for marketing of the dTMS device with the H1 coil for the treatment resistant MDD that failed at least one antidepressant during the current episode. The approval was, in part, granted according to the results of a study published in 2015 proving a remission rate of 32% and a response rate of 38% in a sham controlled study.